Caplin Point Laboratories has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026, to the Bombay Stock Exchange and the National Stock Exchange of India. The disclosure covers sustainability metrics across its domestic manufacturing units and subsidiaries, including Caplin Steriles Limited and Caplin One Labs Limited.

The company reported that its products are exclusively meant for export markets, with operations spanning 57 countries. The reporting boundary includes all units of Caplin Point Laboratories Limited and its Indian subsidiaries, while overseas subsidiaries were excluded as they are primarily involved in marketing activities.

Workforce and Governance

As of March 31, 2026, the company employed a total of 2,877 permanent and non-permanent employees. The workforce composition included 1,745 males (61%) and 1,132 females (39%). Additionally, there were 2,578 workers, comprising 1,466 males (57%) and 1,112 females (43%).

The turnover rate for permanent employees stood at 36.93% in FY26, up from 32.52% in FY25 and 26.9% in FY24. The Board of Directors comprises 24 members, with women representing 12.50% of the total. Key Management Personnel included 11 individuals, with female representation at 27.27%.

Environmental Metrics

The company disclosed significant environmental data for FY26:

Total waste generated increased to 374.07 metric tonnes in FY26 from 350.97 metric tonnes in FY25. Of this, 53.81 metric tonnes were recycled or recovered through various operations.

What the Numbers Show

The data reveals a divergence between energy consumption and intensity metrics. While total energy consumption decreased slightly by 1.4% year-on-year, the energy intensity per rupee of turnover improved significantly, dropping to 0.0000009 GJ/Rupee from 0.0000104 GJ/Rupee in the prior year. This suggests that revenue growth outpaced energy usage during the period.

Assurance and Compliance

M/s Alagar & Associates LLP provided limited assurance on the BRSR Core disclosures. The company reported no fines, penalties, or material non-compliances with environmental laws during the reporting period. It also confirmed zero instances of sexual harassment complaints under the POSH Act and no data breaches involving customer personally identifiable information.

Caplin Point Laboratories ' subsidiary Caplin Steriles received a Form 483 with 10 observations following a USFDA inspection of its facility.

Regulatory development at Caplin Steriles

A Form 483 is issued by the US Food and Drug Administration when investigators observe conditions or practices that may constitute violations of regulations during an inspection. The issuance of a Form 483 does not represent a final agency determination of whether any condition is in violation, but it requires the inspected facility to respond with corrective actions.

Key details of the inspection

Caplin Steriles is the sterile injectables arm of Caplin Point Laboratories, focused on supplying regulated markets including the United States. A USFDA inspection and the subsequent issuance of a Form 483 is a standard part of the agency's oversight process for pharmaceutical manufacturing facilities seeking or maintaining access to the US market.

The company will be required to submit a written response to the USFDA addressing each of the 10 observations within the stipulated timeframe. The outcome of the regulatory process will depend on the adequacy of the corrective and preventive actions proposed by Caplin Steriles in its response.